CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors
Status:
RECRUITING
Trial end date:
2026-06-18
Target enrollment:
Participant gender:
Summary
This study is a multi-center, open, prospective single-arm clinical study of patients with relapsed / refractory B cell hematological tumors to evaluate the safety and efficacy of CD19 \& CD20 bispecific CAR-T cells in relapsed / refractory B cell hematological tumors while collecting pharmacokinetics and pharmacodynamics indicators of CAR-T cells.
Phase:
PHASE1
Details
Lead Sponsor:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborators:
Hebei Taihe Chunyu Biotechnology Co., Ltd Jingzhou Central Hospital Shiyan People's Hospital Xiangyang Central Hospital Yichang Central People's Hospital Zhujiang Hospital